Compare Cadila Healthcare with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs DIVIS LABORATORIES - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE DIVIS LABORATORIES CADILA HEALTHCARE/
DIVIS LABORATORIES
 
P/E (TTM) x 35.4 58.2 60.9% View Chart
P/BV x 6.2 15.6 39.9% View Chart
Dividend Yield % 0.6 0.4 141.5%  

Financials

 CADILA HEALTHCARE   DIVIS LABORATORIES
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-20
DIVIS LABORATORIES
Mar-19
CADILA HEALTHCARE/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3521,639 21.5%   
Low Rs2071,115 18.5%   
Sales per share (Unadj.) Rs139.2186.3 74.7%  
Earnings per share (Unadj.) Rs11.851.0 23.1%  
Cash flow per share (Unadj.) Rs18.657.3 32.4%  
Dividends per share (Unadj.) Rs3.5016.00 21.9%  
Dividend yield (eoy) %1.31.2 107.8%  
Book value per share (Unadj.) Rs101.4261.8 38.7%  
Shares outstanding (eoy) m1,023.74265.47 385.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.07.4 27.2%   
Avg P/E ratio x23.727.0 87.9%  
P/CF ratio (eoy) x15.024.0 62.6%  
Price / Book Value ratio x2.85.3 52.4%  
Dividend payout %29.831.4 94.7%   
Avg Mkt Cap Rs m286,033365,592 78.2%   
No. of employees `00013.411.8 113.2%   
Total wages/salary Rs m24,1455,423 445.3%   
Avg. sales/employee Rs Th10,632.74,175.1 254.7%   
Avg. wages/employee Rs Th1,801.2457.7 393.5%   
Avg. net profit/employee Rs Th898.51,141.8 78.7%   
INCOME DATA
Net Sales Rs m142,53149,463 288.2%  
Other income Rs m1,1391,556 73.2%   
Total revenues Rs m143,67051,019 281.6%   
Gross profit Rs m24,19818,718 129.3%  
Depreciation Rs m6,9651,689 412.4%   
Interest Rs m3,41835 9,765.7%   
Profit before tax Rs m14,95418,551 80.6%   
Minority Interest Rs m2880-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,1985,023 63.7%   
Profit after tax Rs m12,04413,527 89.0%  
Gross profit margin %17.037.8 44.9%  
Effective tax rate %21.427.1 79.0%   
Net profit margin %8.527.3 30.9%  
BALANCE SHEET DATA
Current assets Rs m87,15446,501 187.4%   
Current liabilities Rs m82,6948,468 976.6%   
Net working cap to sales %3.176.9 4.1%  
Current ratio x1.15.5 19.2%  
Inventory Days Days71131 54.6%  
Debtors Days Days9486 109.3%  
Net fixed assets Rs m133,23625,797 516.5%   
Share capital Rs m1,024531 192.9%   
"Free" reserves Rs m102,73368,962 149.0%   
Net worth Rs m103,75769,493 149.3%   
Long term debt Rs m32,1460-   
Total assets Rs m236,86680,383 294.7%  
Interest coverage x5.4531.0 1.0%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.60.6 97.8%   
Return on assets %6.516.9 38.7%  
Return on equity %11.619.5 59.6%  
Return on capital %13.726.7 51.3%  
Exports to sales %00-   
Imports to sales %024.6 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA12,187 0.0%   
Fx inflow Rs m52,75241,238 127.9%   
Fx outflow Rs m14,50412,405 116.9%   
Net fx Rs m38,24828,833 132.7%   
CASH FLOW
From Operations Rs m25,0549,543 262.5%  
From Investments Rs m-10,123-6,854 147.7%  
From Financial Activity Rs m-10,942-2,459 444.9%  
Net Cashflow Rs m3,989230 1,737.4%  

Share Holding

Indian Promoters % 74.8 52.0 143.8%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.3 11.8 70.3%  
FIIs % 5.9 19.0 31.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 17.2 64.0%  
Shareholders   44,069 31,796 138.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   ALEMBIC  SUN PHARMA  IPCA LABS  FDC  AUROBINDO PHARMA  

Compare CADILA HEALTHCARE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty Snap 4-Day Winning Streak; JSW Steel and Hindalco Among Top Losers(Closing)

Indian share markets witnessed selling pressure throughout the day today and ended lower.

Related Views on News

AUROBINDO PHARMA at All Time High; BSE HEALTHCARE Index Up 0.7% (Market Updates)

May 11, 2021 | Updated on May 11, 2021

AUROBINDO PHARMA share price has hit an all time high at Rs 1,064 (up 1.4%). The BSE HEALTHCARE Index is up by 0.7%. Among the top gainers in the BSE HEALTHCARE Index today are AUROBINDO PHARMA (up 1.4%) and PFIZER (up 1.4%). The top losers include PIRAMAL ENTERPRISES and CAPLIN POINT (down 0.2%).

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (3QFY21); Net Profit Up 40.6% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 40.6% YoY). Sales on the other hand came in at Rs 38 bn (up 4.3% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

CADILA HEALTHCARE 2019-20 Annual Report Analysis (Annual Result Update)

Oct 26, 2020 | Updated on Oct 26, 2020

Here's an analysis of the annual report of CADILA HEALTHCARE for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of CADILA HEALTHCARE. Also includes updates on the valuation of CADILA HEALTHCARE.

CADILA HEALTHCARE Announces Quarterly Results (1QFY21); Net Profit Up 49.3% (Quarterly Result Update)

Aug 21, 2020 | Updated on Aug 21, 2020

For the quarter ended June 2020, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (up 49.3% YoY). Sales on the other hand came in at Rs 36 bn (up 4.1% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

More Views on News

Most Popular

The Next Smallcap Winners(Profit Hunter)

Apr 30, 2021

Price is the only due diligence one might require to buy this business.

Time to Buy Smallcaps?(Fast Profits Daily)

Apr 30, 2021

In this video, I'll show you why I favour smallcaps over the Nifty.

Sell in May and Go Away?(Fast Profits Daily)

Apr 28, 2021

Does the concept of selling stocks in the month of May, work in the Indian market?

Are the Stock Markets Deaf to Covid Agony?(Profit Hunter)

May 6, 2021

Why are markets discounting the economic impact of Covid?

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


May 11, 2021 (Close)

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE - TTK HEALTHCARE COMPARISON

COMPARE CADILA HEALTHCARE WITH

MARKET STATS